We are continually acquiring and curating multiple small molecule libraries for plate-based screening.
Parental chemical libraries are stored in argon-sealed plates at -80 °C.
Our current compound collections (~160K in-house diversity compounds) include:
-
The Prestwick chemical library of 1,520 FDA approved off-patent drugs for pilot screening and repurposing studies
-
The Harvard / MIT / Broad Institute Repurposing library of 6,800 FDA-approved, clinical, and advanced preclinical candidates
-
The full NCI NExT collection of 83,536 small molecules for cancer research and three specific subsets (NCI Diversity set VI, NCI Mechanistic set VI, and NCI Natural products set V) comprising 2785 compounds. This general diversity library is designed for the identification of lead compounds for drug discovery projects. The full NExT library is composed of three non-separable subsets from the molecular library small molecule repository (MLSMR) and includes 15 privileged scaffolds from two diversity subsets.
-
We offer 10,000 drug-like macrocycles from ChemBridge for screening against protein-protein interactions among other targets.
-
We offer the Protein Mimetics Library of 8,960 compounds from Enamine for screening against protein-protein interactions among other targets.
-
We offer informer (scaffold) diversity libraries from MedChemExpress (5,000 compounds) and TargetMol (5,000 compounds).
-
We offer the full 50,000-compound MedChemExpress diversity library for screening.
-
We have 500,000 prefractionated natural product extracts from the NCI. Hits from this highly diverse set of compounds will require further collaboration with the NCI to elucidate their structures.
-
We have an agreement in place to access 250,000 open innovation compounds from AstraZeneca Pharmaceuticals for screening at OSU. This library is offered for blind screening where hit series will be provided by AstraZeneca.